Effects of Ginkgo Biloba on Blood Biomarkers in Mild Cognitive Impairment
Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age20+
SponsorHanyang University
About this trial
This study evaluates the effects of Ginkgo biloba on blood biomarkers related to Alzheimer's disease in patients with mild cognitive impairment. Participants will be randomly assigned to receive either Ginkgo biloba or a placebo for 6 months. Changes in blood biomarkers, including p-tau217 and neurofilament light (NfL), as well as cognitive function, will be assessed to determine whether Ginkgo biloba may influence disease-related biological processes.
Eligibility criteria
Qualifiers
Age 20 years or older
Clinical Dementia Rating (CDR) score of 0.5
Patients clinically indicated for treatment with Ginkgo biloba extract
Disqualifiers
Current use of cholinesterase inhibitors such as donepezil, rivastigmine, or galantamine.
Refusal to provide informed consent.
Presence of neurological or psychiatric conditions other than Alzheimer's disease that may affect cognitive function.
Known hypersensitivity to Ginkgo biloba extract or any of its components.
Trial design
Treatments tested in this trial
- Ginkgo Biloba Extract 240 mg
- Placebo
Treatment groups
120 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Hanyang University
Lead sponsor
SK Chemicals
Collaborator
Source ClinicalTrials.gov